A detailed history of Ensign Peak Advisors, Inc transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 443,001 shares of ELDN stock, worth $1.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
443,001
Previous 443,001 -0.0%
Holding current value
$1.71 Million
Previous $1.17 Million 5.65%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$2.17 - $2.75 $771,901 - $978,216
355,715 Added 407.53%
443,001 $1.01 Million
Q3 2022

Nov 14, 2022

BUY
$2.45 - $3.88 $24,955 - $39,521
10,186 Added 13.21%
87,286 $241,000
Q4 2021

Feb 11, 2022

BUY
$4.02 - $6.07 $280,885 - $424,123
69,872 Added 966.69%
77,100 $340,000
Q3 2021

Nov 12, 2021

SELL
$5.94 - $8.46 $171,565 - $244,350
-28,883 Reduced 79.98%
7,228 $45,000
Q4 2020

Feb 12, 2021

BUY
$13.81 - $26.18 $498,692 - $945,385
36,111 New
36,111 $556,000

Others Institutions Holding ELDN

About Eledon Pharmaceuticals, Inc.


  • Ticker ELDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,756,800
  • Market Cap $53.2M
  • Description
  • Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...
More about ELDN
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.